Phase II study of pazopanib with weekly paclitaxel in refractory urothelial cancer.

Genitourinary Cancer
Session Type and Session Title: 
Oral Abstract Session: Urothelial Carcinoma; Penile, Testicular, and Urethral Cancers
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Abstract Number: 


Poster Board Number: 
General Poster Session B (Board #A6)
J Clin Oncol 33, 2015 (suppl 7; abstr 294)
Sandy Srinivas, Sujata Narayanan, Lauren Christine Harshman, Russell Kent Pachynski, Anthony P. Lam, Alice C. Fan, Shermeen Poushnejad, Denise Haas, Ulka N. Vaishampayan; Stanford University Medical Center, Stanford, CA; Stanford University, Stanford, CA; Dana-Farber Cancer Institute, Boston, MA; Washington University School of Medicine in St. Louis, St. Louis, MO; Stanford Cancer Institute, Stanford, CA; Karmanos Cancer Institute, Wayne State University, Detroit, MI

Abstract Disclosures


Background: Currently, there are no standard treatments for relapsed or refractory urothelial carcinoma (UC). Discouraging results have been observed in trials evaluating established chemotherapeutics as single agents or in combination regimens. Paclitaxel has moderate activity when used alone and in combination in UC. Pazopanib is active in other solid tumors secondary to its potent anti-angiogenic effects. We report the results of a multi-center phase II study evaluating the combination of paclitaxel with pazopanib in refractory UC. Methods: Eligible patients (pts) had histologically confirmed UC, with disease that progressed on upto 2 chemotherapeutic regimens. Pazopanib (800 mg) was administered daily, with weekly paclitaxel (80mg/m2) for 3 weeks in a 28 day cycle. Treatment was continued until disease progression or unacceptable toxicity. The primary endpoint of the study was response-rate (RR) based on RECISTv 1.1 criteria. Secondary endpoints included safety, and progression free-survival (PFS). Results: From April 2010 to September 2014, 32 patients were enrolled. Median age was 67 years (29-89) and median ECOG performance status was 1 (0-2). 17 pts (54%) had UC of the upper urinary tract disease and 15(47%) had primary bladder tumors. All pts had multiple metastatic sites, including 9 (28%) with liver metastases. Median number of prior cytotoxic regimens was 2, and 50% were considered cisplatin responsive. Objective responses were observed in 58% with 3 (12%) complete responses (CR), and 12 pts (46%) with partial responses (PR). Another 9 (35%) acheived stable disease (SD). High grade toxicities included grade 3 hypertension (n=2), grade 3 fatigue (n=4), grade 3 thrombosis (n=2) and grade 4 neutropenia (n=2). Nearly half of the patients( n= 14 ) required growth factor support. Conclusions: Our phase II study combining paclitaxel and pazopanib demonstratedsignificant anti-tumor activity in relapsed/refractory UC. This combination is safe, effective and is worthy of evaluation in randomized phase 3 study. Clinical trial information: NCT01108055